Is HRQOL in dialysis associated with patient survival or graft function after kidney transplantation?

BMC Nephrology

Table 5 Characteristics of patients (n = 110) with clinical relevant improvement vs. no improvement in the transition from dialysis to transplantation in the domains “symptoms” and “effect of kidney disease”

	Improvement in symptoms	No improvement in symptoms	p value	Improvement in effect of kidney disease	No improvement in effect of kidney disease	p value
Age^a	48 ± 13	57 ± 16	<0.01	50 ± 15	57 ± 14	0.04
Female, %	32	35	0.74	27	47	0.05
Comorbidity^b	4 (2–6)	5 (4–6)	0.02	4 (3–6)	5 (3–6)	0.53
Time in dialysis^a	1.9 (1.0–2.5)	1.7 (1.3–3.3)	0.36	1.7 (1.1–2.7)	2.2 (1.4–3.7)	0.02
eGFR^c	59 ± 21	56 ± 20	0.40	57 ± 19	61 ± 22	0.30
Living donor,%	26	32	0.47	32	19	0.27

Data presented as mean ± standard deviation or median with interquartile range as appropriate
^aAt time of renal transplantation, in years; ^bCharlson Comorbidity Index in dialysis; ^cEstimated glomerular filtration rate in ml/min/1.73², at time of HRQOL measurement after transplantation

ISSN: 1471-2369